Cite
HARVARD Citation
Peyrin-Biroulet, L. et al. (n.d.). DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn's Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials. Journal of Crohn's and colitis. pp. S119-S121. [Online].